Patents by Inventor Thinnayam N. Krishnamurthy

Thinnayam N. Krishnamurthy has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Controlled release formulations
    Patent number: 10463624
    Abstract: The invention is directed to oral modified/controlled release drug formulations which provide a rapid initial onset of effect and a prolonged duration of effect. Preferably, the peak concentration is lower than that provided by the reference standard for immediate release formulations of the drug, and the duration of effect falls rapidly at the end of the dosing interval.
    Type: Grant
    Filed: September 25, 2017
    Date of Patent: November 5, 2019
    Assignee: RHODES PHARMACEUTICALS L.P.
    Inventors: Thinnayam N. Krishnamurthy, Andrew Darke
  • Methods of treating attention deficit hyperactivity disorder
    Patent number: 10039719
    Abstract: The invention is directed to oral modified/controlled release drug formulations which provide a rapid initial onset of effect and a prolonged duration of effect. Preferably, the peak concentration is lower than that provided by the reference standard for immediate release formulations of the drug, and the duration of effect falls rapidly at the end of the dosing interval.
    Type: Grant
    Filed: September 25, 2017
    Date of Patent: August 7, 2018
    Assignee: RHODES PHARMACEUTICALS L.P.
    Inventors: Thinnayam N. Krishnamurthy, Andrew Darke
  • Methods of preparing oral controlled release formulations
    Patent number: 10022330
    Abstract: The invention is directed to oral modified/controlled release drug formulations which provide a rapid initial onset of effect and a prolonged duration of effect. Preferably, the peak concentration is lower than that provided by the reference standard for immediate release formulations of the drug, and the duration of effect falls rapidly at the end of the dosing interval.
    Type: Grant
    Filed: November 4, 2016
    Date of Patent: July 17, 2018
    Assignee: Rhodes Pharmaceuticals L.P.
    Inventors: Thinnayam N. Krishnamurthy, Andrew Darke
  • Methods of treating attention deficit hyperactivity disorder
    Patent number: 9949931
    Abstract: The invention is directed to oral modified/controlled release drug formulations which provide a rapid initial onset of effect and a prolonged duration of effect. Preferably, the peak concentration is lower than that provided by the reference standard for immediate release formulations of the drug, and the duration of effect falls rapidly at the end of the dosing interval.
    Type: Grant
    Filed: November 4, 2016
    Date of Patent: April 24, 2018
    Assignee: Rhodes Pharmaceuticals L.P.
    Inventors: Thinnayam N. Krishnamurthy, Andrew Darke
  • Methods of treating attention deficit hyperactivity disorder
    Publication number: 20180042854
    Abstract: The invention is directed to oral modified/controlled release drug formulations which provide a rapid initial onset of effect and a prolonged duration of effect. Preferably, the peak concentration is lower than that provided by the reference standard for immediate release formulations of the drug, and the duration of effect falls rapidly at the end of the dosing interval.
    Type: Application
    Filed: September 25, 2017
    Publication date: February 15, 2018
    Inventors: Thinnayam N. Krishnamurthy, Andrew Darke
  • CONTROLLED RELEASE FORMULATIONS
    Publication number: 20180008544
    Abstract: The invention is directed to oral modified/controlled release drug formulations which provide a rapid initial onset of effect and a prolonged duration of effect. Preferably, the peak concentration is lower than that provided by the reference standard for immediate release formulations of the drug, and the duration of effect falls rapidly at the end of the dosing interval.
    Type: Application
    Filed: September 25, 2017
    Publication date: January 11, 2018
    Inventors: Thinnayam N. Krishnamurthy, Andrew Darke
  • Controlled release formulations having rapid onset and rapid decline of effective plasma drug concentrations
    Patent number: 9801823
    Abstract: The invention is directed to oral modified/controlled release drug formulations which provide a rapid initial onset of effect and a prolonged duration of effect. Preferably, the peak concentration is lower than that provided by the reference standard for immediate release formulations of the drug, and the duration of effect falls rapidly at the end of the dosing interval.
    Type: Grant
    Filed: May 21, 2015
    Date of Patent: October 31, 2017
    Assignee: RHODES PHARMACEUTICALS L.P.
    Inventors: Thinnayam N. Krishnamurthy, Andrew Darke
  • CONTROLLED RELEASE FORMULATIONS HAVING RAPID ONSET AND RAPID DECLINE OF EFFECTIVE PLASMA DRUG CONCENTRATIONS
    Publication number: 20170135999
    Abstract: The invention is directed to oral modified/controlled release drug formulations which provide a rapid initial onset of effect and a prolonged duration of effect. Preferably, the peak concentration is lower than that provided by the reference standard for immediate release formulations of the drug, and the duration of effect falls rapidly at the end of the dosing interval.
    Type: Application
    Filed: November 4, 2016
    Publication date: May 18, 2017
    Inventors: Thinnayam N. Krishnamurthy, Andrew Darke
  • METHODS OF PREPARING ORAL CONTROLLED RELEASE FORMULATIONS
    Publication number: 20170079921
    Abstract: The invention is directed to oral modified/controlled release drug formulations which provide a rapid initial onset of effect and a prolonged duration of effect. Preferably, the peak concentration is lower than that provided by the reference standard for immediate release formulations of the drug, and the duration of effect falls rapidly at the end of the dosing interval.
    Type: Application
    Filed: November 4, 2016
    Publication date: March 23, 2017
    Inventors: Thinnayam N. Krishnamurthy, M1V 3J9 Darke
  • METHODS OF TREATING ATTENTION DEFICIT HYPERACTIVITY DISORDER
    Publication number: 20170071926
    Abstract: The invention is directed to oral modified/controlled release drug formulations which provide a rapid initial onset of effect and a prolonged duration of effect. Preferably, the peak concentration is lower than that provided by the reference standard for immediate release formulations of the drug, and the duration of effect falls rapidly at the end of the dosing interval.
    Type: Application
    Filed: November 4, 2016
    Publication date: March 16, 2017
    Inventors: Thinnayam N. Krishnamurthy, Andrew Darke
  • CONTROLLED RELEASE FORMULATIONS HAVING RAPID ONSET AND RAPID DECLINE OF EFFECTIVE PLASMA DRUG CONCENTRATIONS
    Publication number: 20150313850
    Abstract: The invention is directed to oral modified/controlled release drug formulations which provide a rapid initial onset of effect and a prolonged duration of effect. Preferably, the peak concentration is lower than that provided by the reference standard for immediate release formulations of the drug, and the duration of effect falls rapidly at the end of the dosing interval.
    Type: Application
    Filed: May 21, 2015
    Publication date: November 5, 2015
    Inventors: Thinnayam N. Krishnamurthy, Andrew Darke
  • Controlled release formulations having rapid onset and rapid decline of effective plasma drug concentrations
    Patent number: 9066869
    Abstract: The invention is directed to oral modified/controlled release drug formulations which provide a rapid initial onset of effect and a prolonged duration of effect. Preferably, the peak concentration is lower than that provided by the reference standard for immediate release formulations of the drug, and the duration of effect falls rapidly at the end of the dosing interval.
    Type: Grant
    Filed: October 9, 2013
    Date of Patent: June 30, 2015
    Assignee: Purdue Pharma
    Inventors: Thinnayam N. Krishnamurthy, Andrew Darke
  • CONTROLLED RELEASE FORMULATIONS HAVING RAPID ONSET AND RAPID DECLINE OF EFFECTIVE PLASMA DRUG CONCENTRATIONS
    Publication number: 20140099361
    Abstract: The invention is directed to oral modified/controlled release drug formulations which provide a rapid initial onset of effect and a prolonged duration of effect. Preferably, the peak concentration is lower than that provided by the reference standard for immediate release formulations of the drug, and the duration of effect falls rapidly at the end of the dosing interval.
    Type: Application
    Filed: October 9, 2013
    Publication date: April 10, 2014
    Applicant: PURDUE PHARMA
    Inventors: Thinnayam N. Krishnamurthy, Andrew Darke
  • Controlled release formulations having rapid onset and rapid decline of effective plasma drug concentrations
    Patent number: 8580310
    Abstract: The invention is directed to oral modified/controlled release drug formulations which provide a rapid initial onset of effect and a prolonged duration of effect. Preferably, the peak concentration is lower than that provided by the reference standard for immediate release formulations of the drug, and the duration of effect falls rapidly at the end of the dosing interval.
    Type: Grant
    Filed: September 11, 2008
    Date of Patent: November 12, 2013
    Assignee: Purdue Pharma
    Inventors: Thinnayam N. Krishnamurthy, Andrew Darke
  • Controlled release formulations having rapid onset and rapid decline of effective plasma drug concentrations
    Publication number: 20090123554
    Abstract: The invention is directed to oral modified/controlled release drug formulations which provide a rapid initial onset of effect and a prolonged duration of effect. Preferably, the peak concentration is lower than that provided by the reference standard for immediate release formulations of the drug, and the duration of effect falls rapidly at the end of the dosing interval.
    Type: Application
    Filed: September 11, 2008
    Publication date: May 14, 2009
    Applicant: Purdue Pharma
    Inventors: Thinnayam N. Krishnamurthy, Andrew Darke
  • Controlled release formulations having rapid onset and rapid decline of effective plasma drug concentrations
    Patent number: 7438930
    Abstract: The invention is directed to oral modified/controlled release drug formulations which provide a rapid initial onset of effect and a prolonged duration of effect. Preferably, the peak concentration is lower than that provided by the reference standard for immediate release formulations of the drug, and the duration of effect falls rapidly at the end of the dosing interval.
    Type: Grant
    Filed: July 17, 2007
    Date of Patent: October 21, 2008
    Assignee: Purdue Pharma
    Inventors: Thinnayam N. Krishnamurthy, Andrew Darke
  • Controlled release formulations having rapid onset and rapid decline of effective plasma drug concentrations
    Patent number: 7247318
    Abstract: The invention is directed to oral modified/controlled release drug formulations which provide a rapid initial onset of effect and a prolonged duration of effect. Preferably, the peak concentration is lower than that provided by the reference standard for immediate release formulations of the drug, and the duration of effect falls rapidly at the end of the dosing interval.
    Type: Grant
    Filed: May 28, 2002
    Date of Patent: July 24, 2007
    Assignee: Purdue Pharma
    Inventors: Thinnayam N. Krishnamurthy, Andrew Darke
  • Controlled/modified release oral methylphenidate formulations
    Patent number: 7083808
    Abstract: The invention is directed to oral modified/controlled release methylphenidate formulations which provide a rapid initial onset of effect and a prolonged duration of effect. Preferably, the peak concentration is lower than that provided by the reference standard for immediate release methylphenidate formulations, and the duration of effect falls rapidly at the end of the dosing interval so as not to affect the appetite of the patient at dinner nor the patient's sleep thereafter.
    Type: Grant
    Filed: December 19, 2003
    Date of Patent: August 1, 2006
    Assignee: Euro-Celtique S.A.
    Inventors: Paul D. Goldenheim, Richard S. Sackler, Thinnayam N. Krishnamurthy, Andrew Darke, Benjamin Oshlaci
  • Controlled/modified release oral methylphenidate formulations
    Publication number: 20040131680
    Abstract: The invention is directed to oral modified/controlled release methylphenidate formulations which provide a rapid initial onset of effect and a prolonged duration of effect. Preferably, the peak concentration is lower than that provided by the reference standard for immediate release methylphenidate formulations, and the duration of effect falls rapidly at the end of the dosing interval so as not to affect the appetite of the patient at dinner nor the patient's sleep thereafter.
    Type: Application
    Filed: December 19, 2003
    Publication date: July 8, 2004
    Inventors: Paul D. Goldenheim, Richard S. Sackler, Thinnayam N. Krishnamurthy, Andrew Darke, Benjamin Oshlack
  • Controlled/modified release oral methylphenidate formulations
    Patent number: 6673367
    Abstract: The invention is directed to oral modified/controlled release methylphenidate formulations which provide a rapid initial onset of effect and a prolonged duration of effect. Preferably, the peak concentration is lower than that provided by the reference standard for immediate release methylphenidate formulations, and the duration of effect falls rapidly at the end of the dosing interval so as not to affect the appetite of the patient at dinner nor the patient's sleep thereafter.
    Type: Grant
    Filed: December 16, 1999
    Date of Patent: January 6, 2004
    Assignee: Euro-Celtique, S.A.
    Inventors: Paul D. Goldenheim, Richard S. Sackler, Thinnayam N. Krishnamurthy, Andrew Darke, Benjamin Oshlack